Table 5.

Odds ratio representing relative risks of response R₀ or R₂ compared to response R₁ at 18-month and 24-month follow-up period

Follow-up period	Favorable variables	Reference	Response R0a			Response R2a
			OR	95% CI	P	OR	95% CI	P
M18	Age ≤50 years	Age >50 years	0.91	0.31–2.69	0.867	1.19	0.67–2.12	0.550
	Stages A or B	Stage C	0.53	0.22–1.29	0.16	0.94	0.58–1.51	0.794
	Baseline CD4 cell count of ≥200/mm3	Baseline CD4 cell count of <200/mm3	5.14	2.22–11.89	<0.001	1.14	0.71–1.82	0.587
	Good adherence	Incomplete adherence	0.28	0.09–0.83	0.022	2.44	0.93–6.38	0.070
M24	Age ≤50 years	Age >50 years	0.53	0.17–1.62	0.267	0.97	0.54–1.76	0.931
	Stages A or B	Stage C	0.45	0.17–1.19	0.107	0.96	0.58–1.58	0.873
	Baseline CD4 cell count of ≥200/mm3	Baseline CD4 cell count of <200/mm3	2.71	1.06–6.94	0.037	0.82	0.50–1.32	0.413
	Good adherence	Incomplete adherence	0.32	0.12–0.86	0.023	5.82	2.24–15.14	<0.001

Notes:

^aResponses R₀ and R₂ were compared to response R₁; P < 0.05 was considered significant.

Abbreviations: CI, confidence interval; OR, odds ratio; R₀, stabilization or decrease of CD4 cell count compared to the baseline value; R₁, suboptimal immunological response; R₂, optimal immunological response.